Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial
Research output: Contribution to journal › Article › peer-review
Colleges, School and Institutes
- Aston Medical Research Institute, Aston Medical School, Aston Triangle, Birmingham, West Midlands B4 7ET, UK
- University College London Hospitals NHS Foundation Trust
- Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, UK.
- Barts and the London Medical School
- University of Nottingham
Objective: Women with pre-eclampsia have elevated circulating levels of soluble fms-like tyrosine kinase-1 (sFlt-1). Statins can reduce sFlt-1 from cultured cells and improve pregnancy outcome in animals with a pre-eclampsia-like syndrome. We investigated the effect of pravastatin on plasma sFlt-1 levels during pre-eclampsia.
Design: Blinded (clinician and participant), proof of principle, placebo-controlled trial.
Setting: Fifteen UK maternity units.
Population: We used a minimisation algorithm to assign 62 women with early-onset pre-eclampsia (24 +0–31 +6 weeks of gestation) to receive pravastatin 40 mg daily (n = 30) or matched placebo (n = 32), from randomisation to childbirth.
Primary outcome: Difference in mean plasma sFlt-1 levels over the first 3 days following randomisation.
Results: The difference in the mean maternal plasma sFlt-1 levels over the first 3 days after randomisation between the pravastatin (n = 27) and placebo (n = 29) groups was 292 pg/ml (95% CI −1175 to 592; P = 0.5), and over days 1–14 was 48 pg/ml (95% CI −1009 to 913; P = 0.9). Women who received pravastatin had a similar length of pregnancy following randomisation compared with those who received placebo (hazard ratio 0.84; 95% CI 0.50–1.40; P = 0.6). The median time from randomisation to childbirth was 9 days (interquartile range [IQR] 5–14 days) for the pravastatin group and 7 days (IQR 4–11 days) for the placebo group. There were three perinatal deaths in the placebo-treated group and no deaths or serious adverse events attributable to pravastatin.
Conclusions: We found no evidence that pravastatin lowered maternal plasma sFlt-1 levels once early-onset pre-eclampsia had developed. Pravastatin appears to have no adverse perinatal effects.
Tweetable abstract: Pravastatin does not improve maternal plasma sFlt-1 or placental growth factor levels following a diagnosis of early preterm pre-eclampsia #clinicaltrial finds.
|Number of pages||11|
|Journal||BJOG: An International Journal of Obstetrics & Gynaecology|
|Early online date||12 Nov 2019|
|Publication status||Published - Mar 2020|
- anti‐angiogenic factor, double‐blind, perinatal mortality, placebo‐controlled, pravastatin, pre‐eclampsia, randomized trial, statin, pre-eclampsia, randomised trial, placebo-controlled, Anti-angiogenic factor, double-blind, Double-Blind Method, Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage, Humans, Vascular Endothelial Growth Factor Receptor-1/blood, Pre-Eclampsia/blood, Gestational Age, Pregnancy, Adult, Female, Pravastatin/administration & dosage